Indole: A privileged scaffold for the design of anti-cancer agents

被引:361
|
作者
Wan, Yichao [1 ,2 ]
Li, Yuanhua [1 ,2 ]
Yan, Chunxing [1 ,2 ]
Yan, Mi [3 ]
Tang, Zilong [1 ,2 ]
机构
[1] Hunan Univ Sci & Technol, Key Lab Theoret Organ Chem & Funct Mol, Hunan Prov Key Lab Controllable Preparat & Funct, Minist Educ,Sch Chem & Chem Engn, Xiangtan 411201, Hunan, Peoples R China
[2] Hunan Univ Sci & Technol, Hunan Prov Coll, Key Lab QSAR QSPR, Hunan Prov Key Lab Adv Mat New Energy Storage & C, Xiangtan 411201, Hunan, Peoples R China
[3] Shandong Univ, Hosp 2, Dept Pharm, Jinan 250033, Shandong, Peoples R China
基金
中国国家自然科学基金;
关键词
Indole; Drug design; Anti-Cancer; Structure-activity relationships; HISTONE DEACETYLASE INHIBITORS; TUBULIN POLYMERIZATION INHIBITORS; FRAGMENT-BASED METHODS; BIOLOGICAL EVALUATION; MCL-1; INHIBITORS; SELECTIVE INHIBITORS; ANTITUMOR-ACTIVITY; POTENT INHIBITORS; DUAL INHIBITORS; DISCOVERY;
D O I
10.1016/j.ejmech.2019.111691
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
In general, heterocyclic compounds are a significant source of pharmacologically active compounds. Among them, the indole scaffold widely distributes in natural products and bioactive molecules including anti-cancer agents. In view of its unique physic-chemical and biological properties, it has been used as a privileged scaffold in the anti-cancer agents design. So far, many natural and synthetic indole derivatives have been discovered as promising anti-cancer agents used in clinic or clinical evaluations, suggesting its prominent place in anti-cancer drugs development. This review aimed to provide a clear knowledge on the recent development of indoles as anti-cancer agents, such as myeloid cell leukemia-1 (Mcl-1) inhibitors, proviral insertion site in moloney murine leukemia virus (Pim) inhibitors, histone deacetylase (HDAC) inhibitors, silent mating type information regulation 2 homolog (SIRT) inhibitors and tubulin inhibitors, and made an insight into the corresponding structure-activity relationships (SARs). We hope the review could give a guide to develop new anti-cancer agents with greater potency against drug-sensitive and drug-resistant cancers in the future. (C) 2019 Elsevier Masson SAS. All rights reserved.
引用
收藏
页数:18
相关论文
共 50 条